EFMC-ASMC'17

Programme

Sunday August 27, 2017

Excursion 1

Registration

Excursion 2

Opening

Karin BRINER (NOVARTIS, South San Francisco, United States)
Erick M. CARREIRA (ETH ZÜRICH, Zürich, Switzerland)
Koen AUGUSTYNS (UNIVERSITY OF ANTWERP, Antwerp, Belgium)
Gene VAISBERG (CHEMBRIDGE CORPORATION, San Diego, United States)
Thierry LANGER (UNIVERSITY OF VIENNA, Vienna, Austria)

Opening Lecture
T01 - Photochemistry and Photopharmacology in Medicine

Dirk TRAUNER
(NEW YORK UNIVERSITY, New York, United States)

Welcome Reception

Programme

Monday August 28, 2017

Session chair
Erick M. CARREIRA
(ETH ZÜRICH, Zürich, Switzerland)

T02 - Next-Generation Small Molecule Therapeutics
James E BRADNER
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, MA, United States)

T03 - Drugging the Undruggable
Mark BUNNAGE
(VERTEX PHARMACEUTICALS, Boston, United States)

OC01 - Stereoselective Peptide Modifications – Efficient Tools for Natural Product and Drug Synthesis
Uli KAZMAIER
(SAARLAND UNIVERSITY, Saarbrücken, Germany)

Coffee Break and Exhibition

T04 - Bioinspired Asymmetric Catalysis
Helma WENNEMERS
(ETH ZURICH, Zürich, Switzerland)

T05 - Strategies to Facilitate the Discovery of Novel CNS PET Ligands
Lei ZHANG
(PFIZER, Cambridge, United States)

OC02 - Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Peter ETTMAYER
(BOEHRINGER-INGELHEIM, Vienna, Austria)

Lunch and Exhibition

Poster Session 1

Session chair
Helma WENNEMERS
(ETH ZURICH, Zürich, Switzerland)

T06 - Single Electron Processes to Enable Organic Synthesis
Gary A. MOLANDER
(UNIVERSITY OF PENNSYLVANIA, Philadelphia, United States)

T07 - Beta-secretase Inhibitors as a Therapy for Alzheimer's Disease – Where Are We Now?
Roland BÜRLI
(ASTRAZENECA, Cambridge, United Kingdom)

OC03 - Mimicking Nature Complexity with 3D-Fragments Assembly
Hugues LEMOINE
(EDELRIS, LYON, France)

Coffee Break and Exhibition

Programme

PRIZE winner EFMC-YMCS 2016
OC04 - Development of Highly Selective and Reversible Diacylglycerol Lipase Inhibitors

Freek JANSSEN
(LEIDEN UNIVERSITY, Nijmegen, The Netherlands)

T08 - Idea2Data: Augmenting Drug Discovery Efforts through Synthetic Reaction Data Mining and Automation

Christos A. NICOLAOU
(ELI LILLY, Indianapolis, United States)

T09 - A RaPID Way to Discover Pseudo-natural Peptides

Hiroaki SUGA
(UNIVERSITY OF TOKYO, Tokyo, Japan)

Closing of the day

Programme

Tuesday August 29, 2017

Session chair
Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium)

T10 - Azidoperfluoroalkanes - Neglected, Stable and Useful Fluorinated Synthons
Petr BEIER
(ACADEMY OF SCIENCES OF THE CZECH REPUBLIC, Prague, Czech Republic)

T11 - HIV-1 Maturation Inhibitors
Nicholas MEANWELL
(BRISTOL MYERS SQUIBB, Wallingford, CT, United States)

OC05 - Discovery of RG7314, a Vasopressin 1a Receptor Antagonist for the Treatment of Social Communication Deficits in Autism Spectrum Disorders
Patrick SCHNIDER
(F. HOFFMANN-LA ROCHE, Schlieren, Switzerland)

Coffee Break and Exhibition

T12 - Organic Synthesis with Rearrangements - Adventures in Total Synthesis
Nuno MAULIDE
(UNIVERSITY OF VIENNA, Vienna, Austria)

T13 - Isosteric-Switch Strategies: New Concepts and Recent Advances
Thomas C. FESSARD
(SPIROCHEM AG, Basel, Switzerland)

OC06 - Expanding Screening Decks by Innovative MCR Scaffolds
Alexander DÖMLING
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

Lunch and Exhibition

Poster Session 2

Session chair
Gene VAISBERG
(CHEMBRIDGE CORPORATION, San Diego, United States)

T14 - Iron(III)-Catalyzed Carbonyl-Olefin Metathesis
Corinna SCHINDLER
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

T15 - Ring Construction by Pd-catalyzed C(sp3)-H Activation
Olivier BAUDOIN
(UNIVERSITY OF BASEL, Basel, Switzerland)

OC07 - The Discovery of Soluble Guanylate Cyclase Stimulators for the Treatment of Pulmonary Arterial Hypertension
Subharekha RAGHAVAN
(MERCK & CO. INC (MSD), Kenilworth, New Jersey, United States)

Programme

Coffee Break and Exhibition

T16 - Merck Drug Discovery through Enabling Capabilities

Petr VACHAL
(MERCK & CO. INC (MSD), Kenilworth, United States)

T17 - Adventures in Catalysis: from Mechanisms to Applications

Franziska SCHOENEBECK
(RWTH AACHEN, Aachen, Germany)

Closing of the day

Programme

Wednesday August 30, 2017

Session chair
Thierry LANGER
(UNIVERSITY OF VIENNA, Vienna, Austria)

T18 - Exploiting Physical Organic Principles in Reaction Design
Ryan GILMOUR
(UNIVERSITY OF MÜNSTER, Münster, Germany)

T19 - Automation, Integration and Miniaturization In Drug Discovery Synthesis
Guido KOCH
(NOVARTIS PHARMA AG, Schlieren, Switzerland)

OC08 - Exploring New Methods for Facile Synthesis of Some Biologically Interesting Molecules
Ming-Hua XU
(SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, Shanghai, China)

Coffee Break and Exhibition

T20 - Design and Evolution of New Biocatalysts for Organic Synthesis
Nicholas John TURNER
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

T21 - With Asymmetric Hydrogenation towards a Scalable, Stereoselective Synthesis of Bitopertin
Michelangelo SCALONE
(F. HOFFMANN-LA ROCHE AG, Basel, Switzerland)

OC09 - Development of Synthesis Strategies to DNA-Encoded Compound Libraries - of a Chemoresistant Sequence, and Micellar Nanoreactors
Andreas BRUNSCHWEIGER
(TU DORTMUND, Dortmund, Germany)

Lunch and Exhibition

Poster Session 3

Session chair
Yves P. AUBERSON
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

T22 - Collaborative Academic/Industrial Research Under the Umbrella of the NSF Center for Selective C-H Functionalization
Huw DAVIES
(EMORY UNIVERSITY, Atlanta, United States)

Roundtable discussion: “Enabling Advances in the Science of Synthesis through Industry-Academic collaborations in the 21st Century”

Coffee Break and Exhibition

Programme

Prize Ceremony

Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium)

EFMC Prize for a Young Medicinal Chemist in Academia
OC10 - Nature-Derived Peptides as Pharmacological Tools to Design Novel Therapeutics

Christian W. GRUBER
(MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria)

EFMC Prize for a Young Medicinal Chemist in Industry:
OC11 - The Development of non-BET Bromodomain Chemical Probes

Phil HUMPHREYS
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

T23 - Strategies towards Increasing the 3-Dimensionality of the Medicinal Chemistry Design Space

Antonia F. STEPAN
(PFIZER, Basel, Switzerland)

Closing of the day

Symposium banquet

Programme

Thursday August 31, 2017

Session chair

Karin BRINER
(NOVARTIS, South San Francisco, United States)

T24 - Synthetic, Mechanistic and Computational Studies on Reactions of Interest

Scott E. DENMARK
(UNIVERSITY OF ILLINOIS, Urbana, United States)

T25 - More Options, More Complexity: Medicinal Chemistry Mastering Mixed Modalities

Werngard CZECHTIZKY
(SANOFI, Mölndal, Sweden)

OC12 - Discovery of UCB0942, the First Rationally Designed Antiepileptic Drug with a Dual Mechanism of Action for the Treatment of Drug-Resistant Epilepsy

Laurent PROVINS
(UCB, Braine-l'Alleud, Belgium)

Coffee break and Exhibition

T26 - DNA Repair Inhibition in Cancer Therapy: DNA-PK Inhibitor M3814

Thomas FUCHSS
(MERCK KGAA, Darmstadt, Germany)

T27 - Late Stage 18F-Fluorination for PET Imaging

Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Poster Prizes Ceremony

Closing remarks

End of the Symposium